Compare CVS Health Corp (CVS) vs Intel Corp (INTC) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Intel (INTC) trades at $101.65, up 1.84% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $267 million in 2025 despite revenue of $52.85 billion, though it beat EPS estimates in recent quarters. Recent news highlights a $20 billion stock offering to fund AI expansion, causing short-term volatility but viewed as strategic for long-term growth.

Outlook is mixed: analyst consensus price target of $116.67 suggests upside, supported by AI investments, but high P/E of 904.17 and negative profit margins pose valuation risks. Key risks include intense competition, execution challenges in foundry growth, and reliance on capital raises amid cash burn in strategic segments.